Lesion macrophages are a key target for the antiatherogenic effects of LXR agonists.
Bradley
Michelle N
MN
Tontonoz
Peter
P
D000818:Animals; D001161:Arteriosclerosis / Q000473:pathology / Q000517:prevention & control*; D004268:DNA-Binding Proteins / Q000819:agonists*; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D000071518:Liver X Receptors; D008264:Macrophages / Q000187:drug effects*; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*
D004268:DNA-Binding Proteins; D000960:Hypolipidemic Agents; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear